We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Mesa Biotech Launches Molecular Test System at AACC 2019

By LabMedica International staff writers
Posted on 06 Aug 2019
Print article
Image: The Accula system for POC testing (Photo courtesy of Mesa Biotech).
Image: The Accula system for POC testing (Photo courtesy of Mesa Biotech).
Mesa Biotech Inc. (San Diego, CA, USA), a privately-held, molecular diagnostic company that has developed an affordable, sample-to-answer, CLIA-waived PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, launched its respiratory syncytial virus test (RSV) at AACC 2019. Mesa demonstrated its expanded, novel Accula Test System at the 71st American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo held on August 4-8, 2019, at the convention center in Anaheim, CA, USA.

Mesa designs, develops, manufactures and commercializes next-generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the POC. Mesa’s Accula System is a sample-to-answer palm-sized, reusable dock with single-use test cassettes. The novel molecular test system is a visually interpreted, FDA-cleared, CLIA-waived PCR platform with the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassay tests, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing.

At AACC 2019, Mesa exhibited the Accula System's RSV and Flu A/Flu B molecular tests, which are distributed by Sekisui Diagnostics in the U.S. under the Silaris brand. Both the Accula Flu A/Flu B and RSV tests are indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

"We are excited to launch our second Accula point-of-care test at AACC," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "Similar to influenza, RSV requires a prompt and accurate diagnosis at the POC so treatment can begin, making our RSV test an important addition to our sample-to-answer PCR testing platform."

Related Links:
Mesa Biotech

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.